Atara Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:AT20 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
18 Nov 24	Sell€14,451	Eric Hyllengren	Individual	1,364	€10.59
18 Nov 24	Sell€10,594	Jill Henrich	Individual	1,000	€10.59
18 Nov 24	Sell€17,629	Anhco Nguyen	Individual	1,664	€10.59
16 Aug 24	Sell€5,808	Jill Henrich	Individual	963	€6.03
16 Aug 24	Sell€6,984	K. Murugan	Individual	1,158	€6.03
16 Aug 24	Sell€6,453	Eric Hyllengren	Individual	1,070	€6.03
16 Aug 24	Sell€10,983	Anhco Nguyen	Individual	1,821	€6.03
16 Aug 24	Sell€18,323	Pascal Touchon	Individual	3,038	€6.03
22 May 24	Buy€5,880,792	Adiumentum Capital Management	Company	322,636.92	€18.23
16 May 24	Sell€14,617	Jill Henrich	Individual	1,030	€14.19
16 May 24	Sell€16,262	Eric Hyllengren	Individual	1,145.92	€14.19
16 May 24	Sell€24,351	Anhco Nguyen	Individual	1,715.96	€14.19
16 May 24	Sell€18,392	K. Murugan	Individual	1,296.04	€14.19
16 May 24	Sell€46,266	Pascal Touchon	Individual	3,260.24	€14.19
04 Mar 24	Sell€2,571	Jill Henrich	Individual	155.16	€16.57
04 Mar 24	Sell€16,469	Pascal Touchon	Individual	993.76	€16.57
04 Mar 24	Sell€4,429	Eric Hyllengren	Individual	267.16	€16.60
04 Mar 24	Sell€6,658	K. Murugan	Individual	401.76	€16.57
04 Mar 24	Sell€7,124	Anhco Nguyen	Individual	429.84	€16.57

Insider Trading Volume

Insider Buying: AT20 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AT20?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	118,422	2.41%
General Public	705,879	14.4%
Hedge Funds	1,119,429	22.8%
Institutions	2,971,319	60.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.5%.

Top Shareholders

Top 25 shareholders own 80.79% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
23.1%	Adiumentum Capital Management	1,133,823	€9.9m	251%	no data
9.2%	Redmile Group, LLC	452,270	€4.0m	22.1%	0.17%
8.27%	EcoR1 Capital, LLC	406,679	€3.6m	0%	0.1%
5.3%	Citadel Advisors LLC	260,480	€2.3m	0%	no data
3.78%	Bank of America Corporation, Asset Management Arm	186,001	€1.6m	-29.3%	no data
3.45%	The Vanguard Group, Inc.	169,336	€1.5m	-15.6%	no data
3.38%	Tavistock Life Sciences	166,000	€1.5m	0%	0.07%
2.85%	Centiva Capital, LP	140,250	€1.2m	0%	0.06%
2.43%	Acadian Asset Management LLC	119,370	€1.0m	13.1%	no data
2.37%	Millennium Management LLC	116,671	€1.0m	707%	no data
2.28%	Vestal Point Capital, LP	112,000	€982.7k	0%	0.06%
2.09%	Qube Research & Technologies Ltd	102,663	€900.8k	0%	no data
1.53%	Tang Capital Management, LLC	75,196	€659.8k	0%	0.06%
1.53%	Kleiner Perkins Caufield & Byers	75,066	€658.6k	0%	0.14%
1.44%	Woodline Partners LP	70,889	€622.0k	-0.15%	0.01%
1.24%	BlackRock, Inc.	61,145	€536.5k	-77.6%	no data
0.94%	Renaissance Technologies LLC	46,064	€404.2k	17.5%	no data
0.87%	Geode Capital Management, LLC	42,677	€374.5k	-50.6%	no data
0.81%	Staley Capital Advisers, Inc.	40,000	€351.0k	0%	0.02%
0.75%	BNP Paribas Arbitrage Sa, Asset Management Arm	36,724	€322.2k	140%	no data
0.74%	PGIM, Inc.	36,340	€318.9k	0%	no data
0.71%	Medical Strategy GmbH, Asset Management Arm	35,046	€307.5k	-20.1%	0.02%
0.64%	Northern Trust Global Investments	31,492	€276.3k	-7.46%	no data
0.58%	Pascal Touchon	28,339	€248.7k	22.4%	no data
0.53%	Charles Schwab Investment Management, Inc.	26,155	€229.5k	-14.1%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/14 17:43
End of Day Share Price	2024/06/18 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Newman	Canaccord Genuity
Yigal Nochomovitz	Citigroup Inc
Jonathan Miller	Evercore ISI